Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 245 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quaternary ammonium Clear all
Recruiting Phase 2 Interventional

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

NCT05241249
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Bethanechol, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

NCT01854658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Pretreatment With Roc on Succinylcholine Myalgias

NCT04581395
View directory record Official record
Conditions
Myalgia
Interventions
non-pretreated Succinylcholine, succinylcholine 1 minute after rocuronium pretreatment, succinylcholine 2 minutes following rocuronium pretreatment
Other · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01202188
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

NCT04774237
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™, BRIMOCHOL™ F, Carbachol
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Glendale, California • Newport Beach, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional

Bethanechol Prior to Pancreatic Surgery

NCT03572283
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Bethanechol
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

NCT01199237
View directory record Official record
Conditions
Airway Reflexes, Protective, Recovery After Neuromuscular Block, Anesthetic Recovery
Interventions
Sevoflurane, Desflurane, Rocuronium, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

NCT05135286
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™ PF, Carbachol PF, Vehicle
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

NCT03513406
View directory record Official record
Conditions
Burns
Interventions
Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Prevention of Exertional Muscle Dysfunction

NCT01722448
View directory record Official record
Conditions
Muscle Dysfunction, Exertional Rhabdomyolysis, Muscle Strength
Interventions
Choline, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional

Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI

NCT02370862
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

NCT05256901
View directory record Official record
Conditions
Appendicitis, Surgery
Interventions
Sugammadex, Neostigmine/Glycopyrrolate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

NCT01712516
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149, QAB149, NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension

NCT04908397
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Carnitine Nutritional Deficiency
Interventions
L-carnitine
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Bethanechol for Improvement of Esophageal Dysmotility

NCT01031043
View directory record Official record
Conditions
Esophageal Dysmotility
Interventions
Bethanechol
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Betaine and Food on Gastric pH

NCT02758015
View directory record Official record
Conditions
Healthy
Interventions
Standardized Meal, Betaine Hydrochloride 1500mg, Betaine Hydrochloride 3000mg, Betaine Hydrochloride 4500mg
Other · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Intraoperative Low Blood Pressure

NCT02726620
View directory record Official record
Conditions
Hypotension
Interventions
Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 100 Years
Enrollment
22,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Acetyl-L-Carnitine in the Treatment of Septic Shock

NCT00592488
View directory record Official record
Conditions
Septic Shock
Interventions
Acetyl-L-Carnitine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals

NCT00158249
View directory record Official record
Conditions
Marijuana Abuse
Interventions
citicoline, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 6, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

NCT01398046
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Dasatinib plus Rabeprazole, Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 6, 2026, 8:23 AM EDT